Atish D. Choudhury, MD, PhD, discusses emerging treatment strategies in metastatic castration-resistant prostate cancer.
Atish D. Choudhury, MD, PhD, co-director of the Prostate Cancer Center and senior physician at Dana-Farber Cancer Institute, as well as an instructor in medicine at Harvard Medical School, discusses emerging treatment strategies in metastatic castration-resistant prostate cancer (mCRPC).
177Lu-PSMA-617, a targeted radioligand therapy, has the potential to emerge as a viable therapeutic option for men with mCRPC, says Choudhury. Findings from the phase 3 VISION trial (NCT03511664), which were presented during the 2021 ASCO Annual Meeting, demonstrated a 40% reduction in the risk of death with 177Lu-PSMA-617 plus standard of care in patients with PSMA-positive mCRPC. Moreover, combining 177Lu-PSMA-617 with other therapeutic agents may yield deeper and more durable responses for this patient population, explains Choudhury.
Further investigation into the clinical utility of other targeted therapies, such as PARP inhibitors, are warranted to determine whether combination approaches in this setting would improve responses for men with mCRPC, concludes Choudhury.